TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01938352

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CR8020
Description: CR8020 15 mg/kg, administered by intravenous infusion

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (hydrous dextrose in water for injection), administered by intravenous infusion
Study: NCT03561922

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RETINA IMPLANT Alpha AMS
Description: Implantation of the subretinal RETINA IMPLANT Alpha AMS
Study: NCT00432055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (Botox)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (saline)
Study: NCT00414349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical analgesic
Description: max. 3 plasters per day for PHN patients max. 4 plasters per day for DPN patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral intake
Description: 300 to 600 mg per day taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical analgesic
Description: 3 plasters for PHN patients per day 4 plasters for DPN patients per day
Study: NCT02996019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrolizumab
Description: Etrolizumab will be administered at a dose of 105 milligrams (mg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etrolizumab
Description: Etrolizumab will be administered at a dose of 105 milligrams (mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrolizumab
Description: Etrolizumab will be administered at a dose of 105 milligrams (mg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etrolizumab
Description: Etrolizumab will be administered at a dose of 105 milligrams (mg).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auto-Injector (AI)
Description: The pre-filled AI will be used to administer etrolizumab.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auto-Injector (AI)
Description: The pre-filled AI will be used to administer etrolizumab.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prefilled Syringe With Needle Safety Device (PFS-NSD)
Description: The PFS-NSD will be used to administer etrolizumab.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prefilled Syringe With Needle Safety Device (PFS-NSD)
Description: The PFS-NSD will be used to administer etrolizumab.
Study: NCT04060914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90mg
Description: Ticagrelor 90 mg plus aspirin for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90mg/60mg
Description: 1 month after treatment with ticagrelor 90 mg plus aspirin, followed by treatment with ticagrelor 60 mg plus aspirin for 11 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 75mg
Description: Clopidogrel 75mg plus aspirin for 12 months
Study: NCT04258280

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education and counseling
Description: Education includes a workbook, counseling includes peer support.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Education includes a workbook.
Study: NCT00866788

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Participants received a single subcutaneous placebo injection on Day 0 of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H1 antihistamines
Description: Patients received one of the following: Cetirizine 10 mg once per day (QD), Levocetirizine dihydrochloride 5 mg QD, Fexofenadine 60 mg twice per day or 180 mg QD, Loratadine 10 mg QD or Desloratadine 5 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H1 antihistamines
Description: Patients received one of the following: Cetirizine 10 mg once per day (QD), Levocetirizine dihydrochloride 5 mg QD, Fexofenadine 60 mg twice per day or 180 mg QD, Loratadine 10 mg QD or Desloratadine 5 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H1 antihistamines
Description: Patients received one of the following: Cetirizine 10 mg once per day (QD), Levocetirizine dihydrochloride 5 mg QD, Fexofenadine 60 mg twice per day or 180 mg QD, Loratadine 10 mg QD or Desloratadine 5 mg QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: H1 antihistamines
Description: Patients received one of the following: Cetirizine 10 mg once per day (QD), Levocetirizine dihydrochloride 5 mg QD, Fexofenadine 60 mg twice per day or 180 mg QD, Loratadine 10 mg QD or Desloratadine 5 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Diphenhydramine was provided and used on an as-needed basis (25 mg per dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Diphenhydramine was provided and used on an as-needed basis (25 mg per dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Diphenhydramine was provided and used on an as-needed basis (25 mg per dose)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diphenhydramine
Description: Diphenhydramine was provided and used on an as-needed basis (25 mg per dose)
Study: NCT01509365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel
Description: 2 tablets of 75 mg clopidogrel for one month followed by standard 75 mg clopidogrel for 3 months to one year.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: 1 tablet of 75 mg clopidogrel for one month followed by standard 75 mg clopidogrel for 3 months to one year.
Study: NCT03940287

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle Energy Technique
Description: Muscle energy technique will be given in two different position. For anterior in- nominate rotation and posterior in- nominate rotation patient position will be in supine lying position.~For weakened muscle,piriformis application the patient should be side-lying position, close to the edge of the table, affected side uppermost, both legs flexed at hip and knee.~The therapists stand facing the patient at hip level,then patient should be close enough to the edge of the table for the therapist to stabilize the pelvis against his trunk. The angle of hip flexion should not exceed 60°, and then places one hand on the contralateral ASIS to prevent pelvic motion, while the other hand is placed against the lateral flexed knee as this is pushed into resisted abduction to contract piriformis.~Isometric contraction should be hold for 3-5 second and that particular method will be repeated for 7-10 times.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotape application
Description: Kinesiotaping will be applied to piriformis muscle and Sacroiliac joint (SIJ). This tape will be applied in I shape to both sides of the spine from sacrum to Anterior Superior Iliac Spine. For SIJ taping same 5 cm KT tape will be used, it will be applied from below posterior sacroiliac spine to opposite side. Here patient should be in standing position.~For Piriformis application patient will be in side lying position where the affected leg will be placed uppermost with hip in flexion, adduction, and internal rotation , then the application will be performed. The base of the tape will be placed over contralateral part of sacrum and then make a Y strip with no tension will be attached over the greater trochanter of femur.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy
Description: Hydro-collator pack will be used superior to the affected area for at-least 15 minute to reduce the stiffness. Hydocollator pack will be wrap twice with a thick towel and then it will be placed to the affected part.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy
Description: Hydro-collator pack will be used superior to the affected area for at-least 15 minute to reduce the stiffness. Hydocollator pack will be wrap twice with a thick towel and then it will be placed to the affected part.
Study: NCT02055833

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intensive nutritional counseling
Description: Intensive nutritional counseling: nutritional counseling + oral nutritional supplements

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional counseling
Description: Nutritional counseling
Study: NCT01956435

Intervention type: DEVICE
Group type: OTHER
Intervention: Excimer Light Treatment
Description: Excimer light treatment will be performed on one leg of every subject as the intervention while the subjects other leg will serve as a control

Intervention type: DEVICE
Group type: OTHER
Intervention: Excimer Light Treatment
Description: Excimer light treatment will be performed on one leg of every subject as the intervention while the subjects other leg will serve as a control
Study: NCT03734575

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ClariCore System
Description: The user will perform a standard trans-perineal biopsy and collect a number of biopsy cores as per standard practice.
Study: NCT01854658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFF MDI (PT003)
Description: GFF MDI administered as two puffs BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP MDI (PT001)
Description: GP MDI administered as two puffs BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF MDI (PT005)
Description: FF MDI administered as two puffs BID
Study: NCT02807753

Intervention type: OTHER
Intervention: Ankle and Knee Magnetic Resonance Imaging
Description: Ankle and Knee Magnetic Resonance Imaging
Study: NCT03093610

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional
Description: Removal of the chest tube after air leakage has ceased and fluid drainage is 200ml/24h or less.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Test
Description: Removal of the chest tube after air leakage has ceased and fluid drainage is 5ml/kg/24h or less.
Study: NCT03916614

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screening Tool for Relief of Trauma (START)
Description: The Screening and Tool for Awareness and Relief of Trauma (START) was developed for patients that come from communities with sustained and persistent trauma. It consists of six screening questions adapted from the validated Primary Care PTSD Screen,\[30\] with input from focus groups, surveys and in-depth interviews with victims of violence. The full START intervention requires 30-45 minutes of structured conversation at the end of which the participant leaves with a better understanding of trauma symptoms as well as on-the-spot instruction on a set of techniques designed to alleviate the symptoms of PTSD. Based on the results of their screening, the participant will be offered up to four techniques to alleviate their symptoms

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard of care
Description: Screening for PTSD and referral for outpatient services if warranted as well as usual care from Violence Prevention and Outreach Program (VPOP) staff.
Study: NCT02324114

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hsp90
Description: Detect plasma Hsp90α concentration
Study: NCT03572413

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low pressure pneumoperitoneum
Description: Lowering intra-abdominal pressure during laparoscopic surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide
Description: Deep (PTC 1-2) versus moderate (TOF count 1-2) neuromuscular block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium bromide
Description: Deep (PTC 1-2) versus moderate (TOF count 1-2) neuromuscular block
Study: NCT04702503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WP1220
Description: Topical administration 2x daily for 84 consecutive days
Study: NCT03412942

Intervention type: DEVICE
Group type: OTHER
Intervention: FISH SP
Description: The device will be used to close the femoral artery after angiogram and/or endovascular procedure.
Study: NCT03910543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Description: Tofacitinib will be administered at a dose of 5 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Description: Tofacitinib will be administered at a dose of 5 mg twice daily
Study: NCT01430702

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computerized medication delivery unit (Electronic Medication Management Assistant (EMMA)
Description: The patient's prescriptions and refills are packaged in standard-sized blister cards and loaded into EMMA units. The EMMMA identifies each medication automatically - no patient input is required. When activated by the patient, the medications are selected from the blister cards and released into the delivery tray. The EMMA will remain in the patient's home for a period of 30-days immediately following hospitalization. After 30 days, the EMMA MDU will become available for the next eligible patient. This maximizes the number of patients that can benefit from the MDU, while addressing the transition period when medication-reconciliation problems are most common.
Study: NCT03766438

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Storytelling Intervention
Description: 12-minute digital storytelling intervention in Spanish, with four individuals explaining their personal Type 2 Diabetes stories.
Study: NCT04290429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teduglutide
Description: Treatment of patients with SR-GI-GVHD with teduglutide
Study: NCT02653079

Intervention type: OTHER
Intervention: Blood Draw and Questionaire
Description: The study is observational. The treatment-plan of the underlying disease remained unchanged. Blood draw from patients at several time points during and after low dose radiation therapy.
Study: NCT03746431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [111In]-FPI-1547 Injection
Description: \[111In\]-FPI-1547 is a targeted radioimmuno-imaging agent that consists of FPI-1175, an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody, a bifunctional chelate, and Indium-111, a radionuclide. Patients will receive \[111In\]-FPI-1547 Injection of 185 MBq (5 mCi) for imaging.
Study: NCT01249300

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT03465488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole Pill 400mg (GSK)
Description: One single dose of 400mg Albendazole is provided at baseline.
Study: NCT00486733

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DermaGold
Description: The first four follow-up study assessment and data collection points will coincide with scheduled operative interventions on the wound guided by clinical situation and the treating physician's judgment (approximately every 3-4 days). Subsequent follow-up study assessment and data collection points will occur on study days 28 ± 3, 42 ± 3, 60 ± 3, and 90 ± 3.
Study: NCT02556034

Intervention type: OTHER
Intervention: Disease evaluation.
Description: Patients will complete a self-evaluation of 28 joint counts for swelling and tenderness and assess their disease activity on a Visual Analog Scale. A 28 joint count and VAS will then be assessed by a nurse and by a rheumatologist. The same rheumatologist will examine all patients and two nurses will each randomly assess half the total enrolled patients. The nurse will be blinded to the patient's joint count and VAS, and similarly, the rheumatologist will be blinded to both the patient and nurse's assessments.
Study: NCT00909766

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Capsules, Oral, 0 mg, once daily, 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Capsules, Oral, 0 mg, once daily, 28 days
Study: NCT02714803

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connective tissue massage and Conservative applications
Description: Connective tissue massage and conservative aplications were applied 5 days per week for a total of 10 sessions for 2 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Classic massage group and Conservative applications
Description: Classic massage and conservative aplications were applied 5 days per week for a total of 10 sessions for 2 weeks.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham massage group and Conservative applications
Description: Sham massage and conservative aplications were applied 5 days per week for a total of 10 sessions for 2 weeks.
Study: NCT01606384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VASOPRESSIN V1B RECEPTOR ANTAGONIST (SSR149415)
Description: Pharmaceutical form: Capsule Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VASOPRESSIN V1B RECEPTOR ANTAGONIST (SSR149415)
Description: Pharmaceutical form: Capsule Route of administration: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Capsule Route of administration: Oral
Study: NCT03238482

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salmeterol-fluticasone
Description: Seretide Diskus 50/250 µg/dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salmeterol-fluticasone
Description: Salmeterol/fluticasone Easyhaler 50/250 µg/dose, product E

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salmeterol-fluticasone
Description: Salmeterol/fluticasone Easyhaler 50/250 µg/dose, product F

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salmeterol-fluticasone
Description: Salmeterol/fluticasone Easyhaler 50/250 µg/dose, product G
Study: NCT03645174

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Using long tube
Description: Fiberoptic-guided intubation through LMA, using long tube

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aintree catheter
Description: Fiberoptic-guided intubation through LMA, using Aintree catheter
Study: NCT04551417

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free graft urethroplasty
Description: Free graft urethroplasty will be performed either with ventral or dorsal onlay of the graft.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Free graft urethroplasty
Description: Free graft urethroplasty will be performed either with ventral or dorsal onlay of the graft.
Study: NCT04470102

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mitral valve repair by edge-to-edge technique
Description: transaortic access for mitral valve repair edge-to-edge

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Septal myectomy
Description: isolated extended septal myectomy
Study: NCT02195557

Intervention type: DRUG
Intervention: Synvisc®
Study: NCT03826602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: 150mg administered orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 850mg administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iohexol
Description: 1500 mg administered intravenously (IV)
Study: NCT04668183

Intervention type: PROCEDURE
Intervention: Pudendal nerve block group
Description: A 22 Gauge 50 mm insulated needle was then introduced in the anterior-posterior direction at the middle of the ultrasound probe's superior edge with an out-of-plane approach and using an inclination of 15° in the sagittal plane. The needle tip's position was identified by direct visualization using the movement of adjacent anatomical structures.

Intervention type: PROCEDURE
Intervention: Dorsal penile nerve block group
Description: Half of the total 0.2 ml/kg dose of 0.25% bupivacaine was administered while observing its distribution with US. The same procedure was then repeated on the other side of the penis.
Study: NCT06368180

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic assisted gait training
Description: is a robotic treadmill training system that uses body weight support to suspend patients by attaching their legs to robotic legs that help them walk

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Body weight supported treadmill training
Description: The Biodex Unweighting System was used to support the child's body weight, by an adjustable harness placed, over the treadmill.
Study: NCT00782041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m²

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FluoroUracil
Description: 2,000 mg/m²

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic acid
Description: 20 mg/m²
Study: NCT03683862

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: orthodontic appliance
Description: Orthodontic device for retention in the upper arch, after the end of orthodontic treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: orthodontic appliance
Description: Orthodontic device for retention in the upper arch, after the end of orthodontic treatment
Study: NCT02214667

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dual-diagnosis motivational interviewing (DDMI)
Description: DDMI is an evidence-based adaptation to motivational interviewing. DDMI incorporates an integrated framework and accommodates cognitive impairments and disordered thinking associated with co-occurring substance use and mental disorders.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated group therapy (IGT)
Description: IGT is an evidence-based practice for treating co-occurring disorders. IGT focuses on relapse prevention by reducing substance use and stabilizing psychiatric symptoms.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Jail and community-based behavioral health services
Description: Existing behavioral health service programs
Study: NCT00349908

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cordis Neurovascular ENTERPRISE Self Expanding Stent System
Description: Implantation of the device ENTERPRISE used to treat symptomatic stenosis in intracranial arteries.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cordis Neurovascular ENTERPRISE Self Expanding Stent System
Description: Implantation of the device ENTERPRISE to treat wide-necked aneurysms
Study: NCT03737175

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carotid Artery Stenting
Description: Carotid Artery Stenting

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carotid Endarterectomy
Description: Carotid Endarterectomy
Study: NCT00931229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entecavir
Description: All eligible patients will receive rituximab-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy according to current treatment guidelines. The primary endpoint of this study is the incidence of HBV reactivation, defined by a greater than 10-fold increase, compared with previous nadir levels, of HBV DNA during rituximab-CHOP chemotherapy and within 1 year after completion of the last course of rituximab-CHOP chemotherapy. Patients who have HBV reactivation during the study period will receive free entecavir treatment, one of the standard treatment for chronic hepatitis B, for 48 weeks.